OPM-101
Cancer resistant to immune checkpoint inhibitors (e.g., Melanoma)
Key Facts
About Oncodesign Precision Medicine
Oncodesign Precision Medicine is a publicly traded French biotech focused on developing precision therapies for resistant cancers and neurodegenerative diseases. Its strategy is built on a proprietary drug discovery engine, Nanocyclix®, which generates highly selective macrocyclic kinase inhibitors, and an AI-driven target identification platform, OncoSNIPER. Key achievements include advancing two clinical-stage assets, OPM-101 (RIPK2 inhibitor for oncology/IBD) and OPM-201 (LRRK2 inhibitor for Parkinson's), with the latter receiving support from The Michael J. Fox Foundation.
View full company profileAbout Oncodesign Precision Medicine
Oncodesign Precision Medicine is a publicly traded French biotech focused on developing precision therapies for resistant cancers and neurodegenerative diseases. Its strategy is built on a proprietary drug discovery engine, Nanocyclix®, which generates highly selective macrocyclic kinase inhibitors, and an AI-driven target identification platform, OncoSNIPER. Key achievements include advancing two clinical-stage assets, OPM-101 (RIPK2 inhibitor for oncology/IBD) and OPM-201 (LRRK2 inhibitor for Parkinson's), with the latter receiving support from The Michael J. Fox Foundation.
View full company profile